Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirdametinib Monotherapy in Adults With NF1 and Cutaneous Neurofibromas
NCT06159166Phase 2Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Feb 2024
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mirdametinib in neurofibromatosis type 1 (NF1), cutaneous neurofibroma (cNF), sponsored by Johns Hopkins University. Started Feb 2024; status: recruiting.
02
Drugs
mirdametinib
03
Conditions
neurofibromatosis type 1 (NF1)cutaneous neurofibroma (cNF)
Beyond the preview
Go deeper on NCT06159166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06159166.